These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 15451146

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
    Blazing MA, de Lemos JA, White HD, Fox KA, Verheugt FW, Ardissino D, DiBattiste PM, Palmisano J, Bilheimer DW, Snapinn SM, Ramsey KE, Gardner LH, Hasselblad V, Pfeffer MA, Lewis EF, Braunwald E, Califf RM, 'A to Z' Investigators.
    JAMA; 2004 Jul 07; 292(1):55-64. PubMed ID: 15238591
    [Abstract] [Full Text] [Related]

  • 3. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin.
    Cohen M, Théroux P, Borzak S, Frey MJ, White HD, Van Mieghem W, Senatore F, Lis J, Mukherjee R, Harris K, Bigonzi F, ACUTE II Investigators.
    Am Heart J; 2002 Sep 07; 144(3):470-7. PubMed ID: 12228784
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
    Mahaffey KW, Ferguson JJ.
    Am Heart J; 2005 Apr 07; 149(4 Suppl):S81-90. PubMed ID: 16124952
    [Abstract] [Full Text] [Related]

  • 6. Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial.
    Morrow DA, Antman EM, Murphy SA, Qin J, Ruda M, Guneri S, Jacob AJ, Budaj A, Braunwald E, TIMI Study Group.
    Am Heart J; 2007 Dec 07; 154(6):1078-84, 1084.e1. PubMed ID: 18035078
    [Abstract] [Full Text] [Related]

  • 7. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.
    Cohen M, Gensini GF, Maritz F, Gurfinkel EP, Huber K, Timerman A, Krzeminska-Pakula M, Danchin N, White HD, Santopinto J, Bigonzi F, Hecquet C, Vittori L, TETAMI Investigators.
    J Am Coll Cardiol; 2003 Oct 15; 42(8):1348-56. PubMed ID: 14563573
    [Abstract] [Full Text] [Related]

  • 8. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
    Gibson CM, Murphy SA, Montalescot G, Morrow DA, Ardissino D, Cohen M, Gulba DC, Kracoff OH, Lewis BS, Roguin N, Antman EM, Braunwald E, ExTRACT-TIMI 25 Investigators.
    J Am Coll Cardiol; 2007 Jun 12; 49(23):2238-46. PubMed ID: 17560287
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes.
    Cohen M, Mahaffey KW, Pieper K, Pollack CV, Antman EM, Hoekstra J, Goodman SG, Langer A, Col JJ, White HD, Califf RM, Ferguson JJ, SYNERGY Trial Investigators.
    J Am Coll Cardiol; 2006 Oct 03; 48(7):1346-54. PubMed ID: 17010793
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.
    Sabatine MS, Morrow DA, Dalby A, Pfisterer M, Duris T, Lopez-Sendon J, Murphy SA, Gao R, Antman EM, Braunwald E, ExTRACT-TIMI 25 Investigators.
    J Am Coll Cardiol; 2007 Jun 12; 49(23):2256-63. PubMed ID: 17560290
    [Abstract] [Full Text] [Related]

  • 12. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M.
    J Invasive Cardiol; 2000 Dec 12; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy.
    Blazing MA, De Lemos JA, Dyke CK, Califf RM, Bilheimer D, Braunwald E.
    Am Heart J; 2001 Aug 12; 142(2):211-7. PubMed ID: 11479456
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.
    Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM, ESSENCE and TIMI 11B Investigators.
    Am Heart J; 2003 Jul 12; 146(1):33-41. PubMed ID: 12851605
    [Abstract] [Full Text] [Related]

  • 17. Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis.
    Giraldez RR, Nicolau JC, Corbalan R, Gurfinkel EP, Juarez U, Lopez-Sendon J, Parkhomenko A, Molhoek P, Mohanavelu S, Morrow DA, Antman EM.
    Eur Heart J; 2007 Jul 12; 28(13):1566-73. PubMed ID: 17562672
    [Abstract] [Full Text] [Related]

  • 18. A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.
    Califf RM, Petersen JL, Hasselblad V, Mahaffey KW, Ferguson JJ.
    Am Heart J; 2005 Apr 12; 149(4 Suppl):S91-9. PubMed ID: 16124953
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis.
    Murphy SA, Gibson CM, Morrow DA, Van de Werf F, Menown IB, Goodman SG, Mahaffey KW, Cohen M, McCabe CH, Antman EM, Braunwald E.
    Eur Heart J; 2007 Sep 12; 28(17):2077-86. PubMed ID: 17600038
    [Abstract] [Full Text] [Related]

  • 20. Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial.
    Fitchett DH, Langer A, Armstrong PW, Tan M, Mendelsohn A, Goodman SG, INTERACT Trial Long-Term Follow-Up Investigators.
    Am Heart J; 2006 Feb 12; 151(2):373-9. PubMed ID: 16442903
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.